Ipamorelin

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue and ghrelin receptor agonist. Unlike Semaglutide, Tirzepatide, and Retatrutide, which are incretin-based therapies targeting GLP-1, GIP, and/or glucagon receptors for diabetes and weight management, or KLOW, which focuses on tissue repair and inflammation, Ipamorelin stimulates the release of growth hormone (GH) by binding to the ghrelin/growth hormone secretagogue receptor (GHSR) in the pituitary gland. This promotes GH release in a selective, dose-dependent manner, with minimal impact on cortisol or prolactin levels, making it a valuable tool for studying growth hormone dynamics and anabolic processes.

Researchers investigate Ipamorelin in controlled laboratory settings and preclinical models to understand its effects on muscle growth, fat metabolism, bone density, and tissue repair. It enhances protein synthesis, supports recovery from injury, and may improve energy expenditure by increasing GH levels, which stimulate insulin-like growth factor-1 (IGF-1) production in the liver. Its short half-life requires frequent dosing in studies, and it is typically explored in contexts like muscle wasting, aging-related decline, or metabolic regulation, though it remains investigational and is not approved for clinical use outside research.